开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：21年10月投出初稿，第一轮外审太慢了，用了5个月。期间圣诞节、新年，再加上全球疫情，我们没有催稿，只能耐着性子等待： -2021年10月14日 Preliminary Manuscript Data Submitted -2021年10月15日 Author Approved Converted Files -2021年10月15日 Under Review -2022年03月16日 Decision Made -2022年03月16日 Decision Sent to Author 第二年3月份，审稿意见回来了，大修。其中一个审稿人疑虑比较多，对我们发现的新现象持有怀疑看法，认为证据不充足，15条大意见条条有针对性；另外的审稿人稍微温和点，总体上肯定了文章的创新性，但是修改意见也不少。主编给了3个月大修时间。 几个主要作者碰头开了几次小组讨论会，制定了补试验方案，两个博士作为主力，几个硕士辅助，一直扎扎实实补试验两个月后发现deadline不够了，又向杂志申请延期1个月。三个月补完试验，一个月修改文章、图片、Response letter。我们的修回信（42页）长度超过了文章（38页）长度了，内容非常丰满，证据可靠，图片漂亮，方法全面，当时自己都觉得文章质量大幅提升，要是不接受可以投15分以上杂志了。在补试验阶段，实验材料和测试成本就花了好多w。 22年七月份投出，结果审稿人很满意，第二轮只用17天，所有审稿人均认为可以直接接受。 -2022年07月02日 Author Approved Converted Files -2022年07月02日 Under Review -2022年07月19日 Decision Made -2022年07月19日 Decision Sent to Author -2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190115, encodeId=6c2421901150d, content=审稿速度:6.0 偏重的研究方向：心脏发育 经验分享：慢！投稿已经5个多月了！还在外审！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4ae5499160, createdName=bwzhang, createdTime=Thu Feb 29 15:31:18 CST 2024, time=2024-02-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2156961, encodeId=68622156961ee, content=偏重的研究方向：肿瘤学 经验分享：投稿已过20天，记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Sun Sep 10 08:26:45 CST 2023, time=2023-09-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165659, encodeId=793621656594a, content=审稿速度:3.0 经验分享：请问各位学长，学姐这个的意思是文章内容不符合期刊要拒稿吗。 Review #2 received Received 29 Oct, 2023 This content is not available. Review #1 received Received 24 Oct, 2023 This content is not available., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7186562135, createdName=ms9000001363974617, createdTime=Mon Oct 30 07:38:54 CST 2023, time=2023-10-30, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2184174, encodeId=7ee321841e410, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单细胞测序 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125b6164757, createdName=ms4000000592594051, createdTime=Fri Jan 26 22:16:32 CST 2024, time=2024-01-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：生物大分子;siRNA;基础医学 经验分享：Stage Start Date Under Review 22nd Aug 23 09:29:31 Author Approved Converted Files 22nd Aug 23 09:29:31 Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问这个是送审，还是还在编辑部，还没到编辑手里？有的人说没有AE assigned，有的说收到邮件了 Stage Start Date Under Review 12th Nov 22 00:30:15 Author Approved Converted Files 12th Nov 22 00:30:15 Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172966, encodeId=257421e296618, content=投稿命中率:25.0 经验分享：写信给编辑部，编辑部回应说编辑决定要2-3个月，这个是认真的吗？ Thank you for your asking. Currently, the paper EMM is under review. I'm sorry I couldn't tell you in detail, and I ask for your understanding. The paper is in the process of the editor checking the paper, and we inform you that it will take about 2-3 months from submission to the first decision letter. Thank you. Sincerely yours, Heehyun Park, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37278348598, createdName=ms7000000868707045, createdTime=Tue Dec 05 09:03:59 CST 2023, time=2023-12-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169916, encodeId=2b31216991665, content=投稿快一个月了，杂志系统一直显示under review。 research square 2023.10.25显示Editor assigned;2023.10.30显示为 submission checks complet...This submission is UNDER CONSIDERATION at Experimental & Molecular Medicine.只能等着吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/B920FCE6F53899E327DE76521BE8DF0F/100, createdBy=f36d2149028, createdName=xiaoyunzju, createdTime=Tue Nov 21 11:05:21 CST 2023, time=2023-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2166339, encodeId=278b216633987, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：审稿速度太慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bff8308329, createdName=ms6000001883965747, createdTime=Thu Nov 02 18:21:11 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省)]

2022-07-23 Lewisrat

审稿速度:12.0 | 投稿命中率:25.0
经验分享：21年10月投出初稿，第一轮外审太慢了，用了5个月。期间圣诞节、新年，再加上全球疫情，我们没有催稿，只能耐着性子等待：

-2021年10月14日 Preliminary Manuscript Data Submitted
-2021年10月15日 Author Approved Converted Files
-2021年10月15日 Under Review
-2022年03月16日 Decision Made
-2022年03月16日 Decision Sent to Author

第二年3月份，审稿意见回来了，大修。其中一个审稿人疑虑比较多，对我们发现的新现象持有怀疑看法，认为证据不充足，15条大意见条条有针对性；另外的审稿人稍微温和点，总体上肯定了文章的创新性，但是修改意见也不少。主编给了3个月大修时间。

几个主要作者碰头开了几次小组讨论会，制定了补试验方案，两个博士作为主力，几个硕士辅助，一直扎扎实实补试验两个月后发现deadline不够了，又向杂志申请延期1个月。三个月补完试验，一个月修改文章、图片、Response letter。我们的修回信（42页）长度超过了文章（38页）长度了，内容非常丰满，证据可靠，图片漂亮，方法全面，当时自己都觉得文章质量大幅提升，要是不接受可以投15分以上杂志了。在补试验阶段，实验材料和测试成本就花了好多w。

22年七月份投出，结果审稿人很满意，第二轮只用17天，所有审稿人均认为可以直接接受。

-2022年07月02日 Author Approved Converted Files
-2022年07月02日 Under Review
-2022年07月19日 Decision Made
-2022年07月19日 Decision Sent to Author
-2022年07月19日 With NPG

124 13

展开13条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：21年10月投出初稿，第一轮外审太慢了，用了5个月。期间圣诞节、新年，再加上全球疫情，我们没有催稿，只能耐着性子等待： -2021年10月14日 Preliminary Manuscript Data Submitted -2021年10月15日 Author Approved Converted Files -2021年10月15日 Under Review -2022年03月16日 Decision Made -2022年03月16日 Decision Sent to Author 第二年3月份，审稿意见回来了，大修。其中一个审稿人疑虑比较多，对我们发现的新现象持有怀疑看法，认为证据不充足，15条大意见条条有针对性；另外的审稿人稍微温和点，总体上肯定了文章的创新性，但是修改意见也不少。主编给了3个月大修时间。 几个主要作者碰头开了几次小组讨论会，制定了补试验方案，两个博士作为主力，几个硕士辅助，一直扎扎实实补试验两个月后发现deadline不够了，又向杂志申请延期1个月。三个月补完试验，一个月修改文章、图片、Response letter。我们的修回信（42页）长度超过了文章（38页）长度了，内容非常丰满，证据可靠，图片漂亮，方法全面，当时自己都觉得文章质量大幅提升，要是不接受可以投15分以上杂志了。在补试验阶段，实验材料和测试成本就花了好多w。 22年七月份投出，结果审稿人很满意，第二轮只用17天，所有审稿人均认为可以直接接受。 -2022年07月02日 Author Approved Converted Files -2022年07月02日 Under Review -2022年07月19日 Decision Made -2022年07月19日 Decision Sent to Author -2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190115, encodeId=6c2421901150d, content=审稿速度:6.0 偏重的研究方向：心脏发育 经验分享：慢！投稿已经5个多月了！还在外审！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4ae5499160, createdName=bwzhang, createdTime=Thu Feb 29 15:31:18 CST 2024, time=2024-02-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2156961, encodeId=68622156961ee, content=偏重的研究方向：肿瘤学 经验分享：投稿已过20天，记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Sun Sep 10 08:26:45 CST 2023, time=2023-09-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165659, encodeId=793621656594a, content=审稿速度:3.0 经验分享：请问各位学长，学姐这个的意思是文章内容不符合期刊要拒稿吗。 Review #2 received Received 29 Oct, 2023 This content is not available. Review #1 received Received 24 Oct, 2023 This content is not available., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7186562135, createdName=ms9000001363974617, createdTime=Mon Oct 30 07:38:54 CST 2023, time=2023-10-30, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2184174, encodeId=7ee321841e410, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单细胞测序 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125b6164757, createdName=ms4000000592594051, createdTime=Fri Jan 26 22:16:32 CST 2024, time=2024-01-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：生物大分子;siRNA;基础医学 经验分享：Stage Start Date Under Review 22nd Aug 23 09:29:31 Author Approved Converted Files 22nd Aug 23 09:29:31 Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问这个是送审，还是还在编辑部，还没到编辑手里？有的人说没有AE assigned，有的说收到邮件了 Stage Start Date Under Review 12th Nov 22 00:30:15 Author Approved Converted Files 12th Nov 22 00:30:15 Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172966, encodeId=257421e296618, content=投稿命中率:25.0 经验分享：写信给编辑部，编辑部回应说编辑决定要2-3个月，这个是认真的吗？ Thank you for your asking. Currently, the paper EMM is under review. I'm sorry I couldn't tell you in detail, and I ask for your understanding. The paper is in the process of the editor checking the paper, and we inform you that it will take about 2-3 months from submission to the first decision letter. Thank you. Sincerely yours, Heehyun Park, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37278348598, createdName=ms7000000868707045, createdTime=Tue Dec 05 09:03:59 CST 2023, time=2023-12-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169916, encodeId=2b31216991665, content=投稿快一个月了，杂志系统一直显示under review。 research square 2023.10.25显示Editor assigned;2023.10.30显示为 submission checks complet...This submission is UNDER CONSIDERATION at Experimental & Molecular Medicine.只能等着吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/B920FCE6F53899E327DE76521BE8DF0F/100, createdBy=f36d2149028, createdName=xiaoyunzju, createdTime=Tue Nov 21 11:05:21 CST 2023, time=2023-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2166339, encodeId=278b216633987, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：审稿速度太慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bff8308329, createdName=ms6000001883965747, createdTime=Thu Nov 02 18:21:11 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省)]

2024-02-29 bwzhang 来自上海

审稿速度:6.0
偏重的研究方向：心脏发育
经验分享：慢！投稿已经5个多月了！还在外审！

80 0

[GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：21年10月投出初稿，第一轮外审太慢了，用了5个月。期间圣诞节、新年，再加上全球疫情，我们没有催稿，只能耐着性子等待： -2021年10月14日 Preliminary Manuscript Data Submitted -2021年10月15日 Author Approved Converted Files -2021年10月15日 Under Review -2022年03月16日 Decision Made -2022年03月16日 Decision Sent to Author 第二年3月份，审稿意见回来了，大修。其中一个审稿人疑虑比较多，对我们发现的新现象持有怀疑看法，认为证据不充足，15条大意见条条有针对性；另外的审稿人稍微温和点，总体上肯定了文章的创新性，但是修改意见也不少。主编给了3个月大修时间。 几个主要作者碰头开了几次小组讨论会，制定了补试验方案，两个博士作为主力，几个硕士辅助，一直扎扎实实补试验两个月后发现deadline不够了，又向杂志申请延期1个月。三个月补完试验，一个月修改文章、图片、Response letter。我们的修回信（42页）长度超过了文章（38页）长度了，内容非常丰满，证据可靠，图片漂亮，方法全面，当时自己都觉得文章质量大幅提升，要是不接受可以投15分以上杂志了。在补试验阶段，实验材料和测试成本就花了好多w。 22年七月份投出，结果审稿人很满意，第二轮只用17天，所有审稿人均认为可以直接接受。 -2022年07月02日 Author Approved Converted Files -2022年07月02日 Under Review -2022年07月19日 Decision Made -2022年07月19日 Decision Sent to Author -2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190115, encodeId=6c2421901150d, content=审稿速度:6.0 偏重的研究方向：心脏发育 经验分享：慢！投稿已经5个多月了！还在外审！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4ae5499160, createdName=bwzhang, createdTime=Thu Feb 29 15:31:18 CST 2024, time=2024-02-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2156961, encodeId=68622156961ee, content=偏重的研究方向：肿瘤学 经验分享：投稿已过20天，记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Sun Sep 10 08:26:45 CST 2023, time=2023-09-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165659, encodeId=793621656594a, content=审稿速度:3.0 经验分享：请问各位学长，学姐这个的意思是文章内容不符合期刊要拒稿吗。 Review #2 received Received 29 Oct, 2023 This content is not available. Review #1 received Received 24 Oct, 2023 This content is not available., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7186562135, createdName=ms9000001363974617, createdTime=Mon Oct 30 07:38:54 CST 2023, time=2023-10-30, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2184174, encodeId=7ee321841e410, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单细胞测序 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125b6164757, createdName=ms4000000592594051, createdTime=Fri Jan 26 22:16:32 CST 2024, time=2024-01-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：生物大分子;siRNA;基础医学 经验分享：Stage Start Date Under Review 22nd Aug 23 09:29:31 Author Approved Converted Files 22nd Aug 23 09:29:31 Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问这个是送审，还是还在编辑部，还没到编辑手里？有的人说没有AE assigned，有的说收到邮件了 Stage Start Date Under Review 12th Nov 22 00:30:15 Author Approved Converted Files 12th Nov 22 00:30:15 Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172966, encodeId=257421e296618, content=投稿命中率:25.0 经验分享：写信给编辑部，编辑部回应说编辑决定要2-3个月，这个是认真的吗？ Thank you for your asking. Currently, the paper EMM is under review. I'm sorry I couldn't tell you in detail, and I ask for your understanding. The paper is in the process of the editor checking the paper, and we inform you that it will take about 2-3 months from submission to the first decision letter. Thank you. Sincerely yours, Heehyun Park, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37278348598, createdName=ms7000000868707045, createdTime=Tue Dec 05 09:03:59 CST 2023, time=2023-12-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169916, encodeId=2b31216991665, content=投稿快一个月了，杂志系统一直显示under review。 research square 2023.10.25显示Editor assigned;2023.10.30显示为 submission checks complet...This submission is UNDER CONSIDERATION at Experimental & Molecular Medicine.只能等着吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/B920FCE6F53899E327DE76521BE8DF0F/100, createdBy=f36d2149028, createdName=xiaoyunzju, createdTime=Tue Nov 21 11:05:21 CST 2023, time=2023-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2166339, encodeId=278b216633987, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：审稿速度太慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bff8308329, createdName=ms6000001883965747, createdTime=Thu Nov 02 18:21:11 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省)]

2023-09-10 ds666888 来自四川省

偏重的研究方向：肿瘤学
经验分享：投稿已过20天，记录一下

114 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：21年10月投出初稿，第一轮外审太慢了，用了5个月。期间圣诞节、新年，再加上全球疫情，我们没有催稿，只能耐着性子等待： -2021年10月14日 Preliminary Manuscript Data Submitted -2021年10月15日 Author Approved Converted Files -2021年10月15日 Under Review -2022年03月16日 Decision Made -2022年03月16日 Decision Sent to Author 第二年3月份，审稿意见回来了，大修。其中一个审稿人疑虑比较多，对我们发现的新现象持有怀疑看法，认为证据不充足，15条大意见条条有针对性；另外的审稿人稍微温和点，总体上肯定了文章的创新性，但是修改意见也不少。主编给了3个月大修时间。 几个主要作者碰头开了几次小组讨论会，制定了补试验方案，两个博士作为主力，几个硕士辅助，一直扎扎实实补试验两个月后发现deadline不够了，又向杂志申请延期1个月。三个月补完试验，一个月修改文章、图片、Response letter。我们的修回信（42页）长度超过了文章（38页）长度了，内容非常丰满，证据可靠，图片漂亮，方法全面，当时自己都觉得文章质量大幅提升，要是不接受可以投15分以上杂志了。在补试验阶段，实验材料和测试成本就花了好多w。 22年七月份投出，结果审稿人很满意，第二轮只用17天，所有审稿人均认为可以直接接受。 -2022年07月02日 Author Approved Converted Files -2022年07月02日 Under Review -2022年07月19日 Decision Made -2022年07月19日 Decision Sent to Author -2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190115, encodeId=6c2421901150d, content=审稿速度:6.0 偏重的研究方向：心脏发育 经验分享：慢！投稿已经5个多月了！还在外审！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4ae5499160, createdName=bwzhang, createdTime=Thu Feb 29 15:31:18 CST 2024, time=2024-02-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2156961, encodeId=68622156961ee, content=偏重的研究方向：肿瘤学 经验分享：投稿已过20天，记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Sun Sep 10 08:26:45 CST 2023, time=2023-09-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165659, encodeId=793621656594a, content=审稿速度:3.0 经验分享：请问各位学长，学姐这个的意思是文章内容不符合期刊要拒稿吗。 Review #2 received Received 29 Oct, 2023 This content is not available. Review #1 received Received 24 Oct, 2023 This content is not available., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7186562135, createdName=ms9000001363974617, createdTime=Mon Oct 30 07:38:54 CST 2023, time=2023-10-30, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2184174, encodeId=7ee321841e410, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单细胞测序 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125b6164757, createdName=ms4000000592594051, createdTime=Fri Jan 26 22:16:32 CST 2024, time=2024-01-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：生物大分子;siRNA;基础医学 经验分享：Stage Start Date Under Review 22nd Aug 23 09:29:31 Author Approved Converted Files 22nd Aug 23 09:29:31 Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问这个是送审，还是还在编辑部，还没到编辑手里？有的人说没有AE assigned，有的说收到邮件了 Stage Start Date Under Review 12th Nov 22 00:30:15 Author Approved Converted Files 12th Nov 22 00:30:15 Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172966, encodeId=257421e296618, content=投稿命中率:25.0 经验分享：写信给编辑部，编辑部回应说编辑决定要2-3个月，这个是认真的吗？ Thank you for your asking. Currently, the paper EMM is under review. I'm sorry I couldn't tell you in detail, and I ask for your understanding. The paper is in the process of the editor checking the paper, and we inform you that it will take about 2-3 months from submission to the first decision letter. Thank you. Sincerely yours, Heehyun Park, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37278348598, createdName=ms7000000868707045, createdTime=Tue Dec 05 09:03:59 CST 2023, time=2023-12-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169916, encodeId=2b31216991665, content=投稿快一个月了，杂志系统一直显示under review。 research square 2023.10.25显示Editor assigned;2023.10.30显示为 submission checks complet...This submission is UNDER CONSIDERATION at Experimental & Molecular Medicine.只能等着吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/B920FCE6F53899E327DE76521BE8DF0F/100, createdBy=f36d2149028, createdName=xiaoyunzju, createdTime=Tue Nov 21 11:05:21 CST 2023, time=2023-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2166339, encodeId=278b216633987, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：审稿速度太慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bff8308329, createdName=ms6000001883965747, createdTime=Thu Nov 02 18:21:11 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省)]

2023-10-30 ms9000001363974617 来自黑龙江省

审稿速度:3.0
经验分享：请问各位学长，学姐这个的意思是文章内容不符合期刊要拒稿吗。
Review #2 received
Received 29 Oct, 2023
This content is not available.
Review #1 received
Received 24 Oct, 2023
This content is not available.

93 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：21年10月投出初稿，第一轮外审太慢了，用了5个月。期间圣诞节、新年，再加上全球疫情，我们没有催稿，只能耐着性子等待： -2021年10月14日 Preliminary Manuscript Data Submitted -2021年10月15日 Author Approved Converted Files -2021年10月15日 Under Review -2022年03月16日 Decision Made -2022年03月16日 Decision Sent to Author 第二年3月份，审稿意见回来了，大修。其中一个审稿人疑虑比较多，对我们发现的新现象持有怀疑看法，认为证据不充足，15条大意见条条有针对性；另外的审稿人稍微温和点，总体上肯定了文章的创新性，但是修改意见也不少。主编给了3个月大修时间。 几个主要作者碰头开了几次小组讨论会，制定了补试验方案，两个博士作为主力，几个硕士辅助，一直扎扎实实补试验两个月后发现deadline不够了，又向杂志申请延期1个月。三个月补完试验，一个月修改文章、图片、Response letter。我们的修回信（42页）长度超过了文章（38页）长度了，内容非常丰满，证据可靠，图片漂亮，方法全面，当时自己都觉得文章质量大幅提升，要是不接受可以投15分以上杂志了。在补试验阶段，实验材料和测试成本就花了好多w。 22年七月份投出，结果审稿人很满意，第二轮只用17天，所有审稿人均认为可以直接接受。 -2022年07月02日 Author Approved Converted Files -2022年07月02日 Under Review -2022年07月19日 Decision Made -2022年07月19日 Decision Sent to Author -2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190115, encodeId=6c2421901150d, content=审稿速度:6.0 偏重的研究方向：心脏发育 经验分享：慢！投稿已经5个多月了！还在外审！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4ae5499160, createdName=bwzhang, createdTime=Thu Feb 29 15:31:18 CST 2024, time=2024-02-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2156961, encodeId=68622156961ee, content=偏重的研究方向：肿瘤学 经验分享：投稿已过20天，记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Sun Sep 10 08:26:45 CST 2023, time=2023-09-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165659, encodeId=793621656594a, content=审稿速度:3.0 经验分享：请问各位学长，学姐这个的意思是文章内容不符合期刊要拒稿吗。 Review #2 received Received 29 Oct, 2023 This content is not available. Review #1 received Received 24 Oct, 2023 This content is not available., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7186562135, createdName=ms9000001363974617, createdTime=Mon Oct 30 07:38:54 CST 2023, time=2023-10-30, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2184174, encodeId=7ee321841e410, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单细胞测序 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125b6164757, createdName=ms4000000592594051, createdTime=Fri Jan 26 22:16:32 CST 2024, time=2024-01-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：生物大分子;siRNA;基础医学 经验分享：Stage Start Date Under Review 22nd Aug 23 09:29:31 Author Approved Converted Files 22nd Aug 23 09:29:31 Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问这个是送审，还是还在编辑部，还没到编辑手里？有的人说没有AE assigned，有的说收到邮件了 Stage Start Date Under Review 12th Nov 22 00:30:15 Author Approved Converted Files 12th Nov 22 00:30:15 Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172966, encodeId=257421e296618, content=投稿命中率:25.0 经验分享：写信给编辑部，编辑部回应说编辑决定要2-3个月，这个是认真的吗？ Thank you for your asking. Currently, the paper EMM is under review. I'm sorry I couldn't tell you in detail, and I ask for your understanding. The paper is in the process of the editor checking the paper, and we inform you that it will take about 2-3 months from submission to the first decision letter. Thank you. Sincerely yours, Heehyun Park, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37278348598, createdName=ms7000000868707045, createdTime=Tue Dec 05 09:03:59 CST 2023, time=2023-12-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169916, encodeId=2b31216991665, content=投稿快一个月了，杂志系统一直显示under review。 research square 2023.10.25显示Editor assigned;2023.10.30显示为 submission checks complet...This submission is UNDER CONSIDERATION at Experimental & Molecular Medicine.只能等着吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/B920FCE6F53899E327DE76521BE8DF0F/100, createdBy=f36d2149028, createdName=xiaoyunzju, createdTime=Tue Nov 21 11:05:21 CST 2023, time=2023-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2166339, encodeId=278b216633987, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：审稿速度太慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bff8308329, createdName=ms6000001883965747, createdTime=Thu Nov 02 18:21:11 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省)]

2024-01-26 ms4000000592594051 来自四川省

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：单细胞测序
经验分享：无

76 0

[GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：21年10月投出初稿，第一轮外审太慢了，用了5个月。期间圣诞节、新年，再加上全球疫情，我们没有催稿，只能耐着性子等待： -2021年10月14日 Preliminary Manuscript Data Submitted -2021年10月15日 Author Approved Converted Files -2021年10月15日 Under Review -2022年03月16日 Decision Made -2022年03月16日 Decision Sent to Author 第二年3月份，审稿意见回来了，大修。其中一个审稿人疑虑比较多，对我们发现的新现象持有怀疑看法，认为证据不充足，15条大意见条条有针对性；另外的审稿人稍微温和点，总体上肯定了文章的创新性，但是修改意见也不少。主编给了3个月大修时间。 几个主要作者碰头开了几次小组讨论会，制定了补试验方案，两个博士作为主力，几个硕士辅助，一直扎扎实实补试验两个月后发现deadline不够了，又向杂志申请延期1个月。三个月补完试验，一个月修改文章、图片、Response letter。我们的修回信（42页）长度超过了文章（38页）长度了，内容非常丰满，证据可靠，图片漂亮，方法全面，当时自己都觉得文章质量大幅提升，要是不接受可以投15分以上杂志了。在补试验阶段，实验材料和测试成本就花了好多w。 22年七月份投出，结果审稿人很满意，第二轮只用17天，所有审稿人均认为可以直接接受。 -2022年07月02日 Author Approved Converted Files -2022年07月02日 Under Review -2022年07月19日 Decision Made -2022年07月19日 Decision Sent to Author -2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190115, encodeId=6c2421901150d, content=审稿速度:6.0 偏重的研究方向：心脏发育 经验分享：慢！投稿已经5个多月了！还在外审！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4ae5499160, createdName=bwzhang, createdTime=Thu Feb 29 15:31:18 CST 2024, time=2024-02-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2156961, encodeId=68622156961ee, content=偏重的研究方向：肿瘤学 经验分享：投稿已过20天，记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Sun Sep 10 08:26:45 CST 2023, time=2023-09-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165659, encodeId=793621656594a, content=审稿速度:3.0 经验分享：请问各位学长，学姐这个的意思是文章内容不符合期刊要拒稿吗。 Review #2 received Received 29 Oct, 2023 This content is not available. Review #1 received Received 24 Oct, 2023 This content is not available., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7186562135, createdName=ms9000001363974617, createdTime=Mon Oct 30 07:38:54 CST 2023, time=2023-10-30, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2184174, encodeId=7ee321841e410, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单细胞测序 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125b6164757, createdName=ms4000000592594051, createdTime=Fri Jan 26 22:16:32 CST 2024, time=2024-01-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：生物大分子;siRNA;基础医学 经验分享：Stage Start Date Under Review 22nd Aug 23 09:29:31 Author Approved Converted Files 22nd Aug 23 09:29:31 Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问这个是送审，还是还在编辑部，还没到编辑手里？有的人说没有AE assigned，有的说收到邮件了 Stage Start Date Under Review 12th Nov 22 00:30:15 Author Approved Converted Files 12th Nov 22 00:30:15 Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172966, encodeId=257421e296618, content=投稿命中率:25.0 经验分享：写信给编辑部，编辑部回应说编辑决定要2-3个月，这个是认真的吗？ Thank you for your asking. Currently, the paper EMM is under review. I'm sorry I couldn't tell you in detail, and I ask for your understanding. The paper is in the process of the editor checking the paper, and we inform you that it will take about 2-3 months from submission to the first decision letter. Thank you. Sincerely yours, Heehyun Park, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37278348598, createdName=ms7000000868707045, createdTime=Tue Dec 05 09:03:59 CST 2023, time=2023-12-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169916, encodeId=2b31216991665, content=投稿快一个月了，杂志系统一直显示under review。 research square 2023.10.25显示Editor assigned;2023.10.30显示为 submission checks complet...This submission is UNDER CONSIDERATION at Experimental & Molecular Medicine.只能等着吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/B920FCE6F53899E327DE76521BE8DF0F/100, createdBy=f36d2149028, createdName=xiaoyunzju, createdTime=Tue Nov 21 11:05:21 CST 2023, time=2023-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2166339, encodeId=278b216633987, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：审稿速度太慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bff8308329, createdName=ms6000001883965747, createdTime=Thu Nov 02 18:21:11 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省)]

2023-09-01 ms6000000371699092 来自上海

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：生物大分子;siRNA;基础医学
经验分享：Stage Start Date
Under Review 22nd Aug 23 09:29:31
Author Approved Converted Files 22nd Aug 23 09:29:31
Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20

123 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：21年10月投出初稿，第一轮外审太慢了，用了5个月。期间圣诞节、新年，再加上全球疫情，我们没有催稿，只能耐着性子等待： -2021年10月14日 Preliminary Manuscript Data Submitted -2021年10月15日 Author Approved Converted Files -2021年10月15日 Under Review -2022年03月16日 Decision Made -2022年03月16日 Decision Sent to Author 第二年3月份，审稿意见回来了，大修。其中一个审稿人疑虑比较多，对我们发现的新现象持有怀疑看法，认为证据不充足，15条大意见条条有针对性；另外的审稿人稍微温和点，总体上肯定了文章的创新性，但是修改意见也不少。主编给了3个月大修时间。 几个主要作者碰头开了几次小组讨论会，制定了补试验方案，两个博士作为主力，几个硕士辅助，一直扎扎实实补试验两个月后发现deadline不够了，又向杂志申请延期1个月。三个月补完试验，一个月修改文章、图片、Response letter。我们的修回信（42页）长度超过了文章（38页）长度了，内容非常丰满，证据可靠，图片漂亮，方法全面，当时自己都觉得文章质量大幅提升，要是不接受可以投15分以上杂志了。在补试验阶段，实验材料和测试成本就花了好多w。 22年七月份投出，结果审稿人很满意，第二轮只用17天，所有审稿人均认为可以直接接受。 -2022年07月02日 Author Approved Converted Files -2022年07月02日 Under Review -2022年07月19日 Decision Made -2022年07月19日 Decision Sent to Author -2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190115, encodeId=6c2421901150d, content=审稿速度:6.0 偏重的研究方向：心脏发育 经验分享：慢！投稿已经5个多月了！还在外审！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4ae5499160, createdName=bwzhang, createdTime=Thu Feb 29 15:31:18 CST 2024, time=2024-02-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2156961, encodeId=68622156961ee, content=偏重的研究方向：肿瘤学 经验分享：投稿已过20天，记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Sun Sep 10 08:26:45 CST 2023, time=2023-09-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165659, encodeId=793621656594a, content=审稿速度:3.0 经验分享：请问各位学长，学姐这个的意思是文章内容不符合期刊要拒稿吗。 Review #2 received Received 29 Oct, 2023 This content is not available. Review #1 received Received 24 Oct, 2023 This content is not available., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7186562135, createdName=ms9000001363974617, createdTime=Mon Oct 30 07:38:54 CST 2023, time=2023-10-30, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2184174, encodeId=7ee321841e410, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单细胞测序 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125b6164757, createdName=ms4000000592594051, createdTime=Fri Jan 26 22:16:32 CST 2024, time=2024-01-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：生物大分子;siRNA;基础医学 经验分享：Stage Start Date Under Review 22nd Aug 23 09:29:31 Author Approved Converted Files 22nd Aug 23 09:29:31 Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问这个是送审，还是还在编辑部，还没到编辑手里？有的人说没有AE assigned，有的说收到邮件了 Stage Start Date Under Review 12th Nov 22 00:30:15 Author Approved Converted Files 12th Nov 22 00:30:15 Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172966, encodeId=257421e296618, content=投稿命中率:25.0 经验分享：写信给编辑部，编辑部回应说编辑决定要2-3个月，这个是认真的吗？ Thank you for your asking. Currently, the paper EMM is under review. I'm sorry I couldn't tell you in detail, and I ask for your understanding. The paper is in the process of the editor checking the paper, and we inform you that it will take about 2-3 months from submission to the first decision letter. Thank you. Sincerely yours, Heehyun Park, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37278348598, createdName=ms7000000868707045, createdTime=Tue Dec 05 09:03:59 CST 2023, time=2023-12-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169916, encodeId=2b31216991665, content=投稿快一个月了，杂志系统一直显示under review。 research square 2023.10.25显示Editor assigned;2023.10.30显示为 submission checks complet...This submission is UNDER CONSIDERATION at Experimental & Molecular Medicine.只能等着吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/B920FCE6F53899E327DE76521BE8DF0F/100, createdBy=f36d2149028, createdName=xiaoyunzju, createdTime=Tue Nov 21 11:05:21 CST 2023, time=2023-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2166339, encodeId=278b216633987, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：审稿速度太慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bff8308329, createdName=ms6000001883965747, createdTime=Thu Nov 02 18:21:11 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省)]

2022-11-16 JayNi

审稿速度:3.0 | 投稿命中率:50.0
经验分享：请问这个是送审，还是还在编辑部，还没到编辑手里？有的人说没有AE assigned，有的说收到邮件了
Stage Start Date
Under Review 12th Nov 22 00:30:15
Author Approved Converted Files 12th Nov 22 00:30:15
Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58

124 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：21年10月投出初稿，第一轮外审太慢了，用了5个月。期间圣诞节、新年，再加上全球疫情，我们没有催稿，只能耐着性子等待： -2021年10月14日 Preliminary Manuscript Data Submitted -2021年10月15日 Author Approved Converted Files -2021年10月15日 Under Review -2022年03月16日 Decision Made -2022年03月16日 Decision Sent to Author 第二年3月份，审稿意见回来了，大修。其中一个审稿人疑虑比较多，对我们发现的新现象持有怀疑看法，认为证据不充足，15条大意见条条有针对性；另外的审稿人稍微温和点，总体上肯定了文章的创新性，但是修改意见也不少。主编给了3个月大修时间。 几个主要作者碰头开了几次小组讨论会，制定了补试验方案，两个博士作为主力，几个硕士辅助，一直扎扎实实补试验两个月后发现deadline不够了，又向杂志申请延期1个月。三个月补完试验，一个月修改文章、图片、Response letter。我们的修回信（42页）长度超过了文章（38页）长度了，内容非常丰满，证据可靠，图片漂亮，方法全面，当时自己都觉得文章质量大幅提升，要是不接受可以投15分以上杂志了。在补试验阶段，实验材料和测试成本就花了好多w。 22年七月份投出，结果审稿人很满意，第二轮只用17天，所有审稿人均认为可以直接接受。 -2022年07月02日 Author Approved Converted Files -2022年07月02日 Under Review -2022年07月19日 Decision Made -2022年07月19日 Decision Sent to Author -2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190115, encodeId=6c2421901150d, content=审稿速度:6.0 偏重的研究方向：心脏发育 经验分享：慢！投稿已经5个多月了！还在外审！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4ae5499160, createdName=bwzhang, createdTime=Thu Feb 29 15:31:18 CST 2024, time=2024-02-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2156961, encodeId=68622156961ee, content=偏重的研究方向：肿瘤学 经验分享：投稿已过20天，记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Sun Sep 10 08:26:45 CST 2023, time=2023-09-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165659, encodeId=793621656594a, content=审稿速度:3.0 经验分享：请问各位学长，学姐这个的意思是文章内容不符合期刊要拒稿吗。 Review #2 received Received 29 Oct, 2023 This content is not available. Review #1 received Received 24 Oct, 2023 This content is not available., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7186562135, createdName=ms9000001363974617, createdTime=Mon Oct 30 07:38:54 CST 2023, time=2023-10-30, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2184174, encodeId=7ee321841e410, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单细胞测序 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125b6164757, createdName=ms4000000592594051, createdTime=Fri Jan 26 22:16:32 CST 2024, time=2024-01-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：生物大分子;siRNA;基础医学 经验分享：Stage Start Date Under Review 22nd Aug 23 09:29:31 Author Approved Converted Files 22nd Aug 23 09:29:31 Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问这个是送审，还是还在编辑部，还没到编辑手里？有的人说没有AE assigned，有的说收到邮件了 Stage Start Date Under Review 12th Nov 22 00:30:15 Author Approved Converted Files 12th Nov 22 00:30:15 Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172966, encodeId=257421e296618, content=投稿命中率:25.0 经验分享：写信给编辑部，编辑部回应说编辑决定要2-3个月，这个是认真的吗？ Thank you for your asking. Currently, the paper EMM is under review. I'm sorry I couldn't tell you in detail, and I ask for your understanding. The paper is in the process of the editor checking the paper, and we inform you that it will take about 2-3 months from submission to the first decision letter. Thank you. Sincerely yours, Heehyun Park, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37278348598, createdName=ms7000000868707045, createdTime=Tue Dec 05 09:03:59 CST 2023, time=2023-12-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169916, encodeId=2b31216991665, content=投稿快一个月了，杂志系统一直显示under review。 research square 2023.10.25显示Editor assigned;2023.10.30显示为 submission checks complet...This submission is UNDER CONSIDERATION at Experimental & Molecular Medicine.只能等着吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/B920FCE6F53899E327DE76521BE8DF0F/100, createdBy=f36d2149028, createdName=xiaoyunzju, createdTime=Tue Nov 21 11:05:21 CST 2023, time=2023-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2166339, encodeId=278b216633987, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：审稿速度太慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bff8308329, createdName=ms6000001883965747, createdTime=Thu Nov 02 18:21:11 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省)]

2023-12-05 ms7000000868707045 来自湖南省

投稿命中率:25.0
经验分享：写信给编辑部，编辑部回应说编辑决定要2-3个月，这个是认真的吗？ Thank you for your asking. Currently, the paper EMM is under review. I'm sorry I couldn't tell you in detail, and I ask for your understanding. The paper is in the process of the editor checking the paper, and we inform you that it will take about 2-3 months from submission to the first decision letter. Thank you. Sincerely yours, Heehyun Park

105 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：21年10月投出初稿，第一轮外审太慢了，用了5个月。期间圣诞节、新年，再加上全球疫情，我们没有催稿，只能耐着性子等待： -2021年10月14日 Preliminary Manuscript Data Submitted -2021年10月15日 Author Approved Converted Files -2021年10月15日 Under Review -2022年03月16日 Decision Made -2022年03月16日 Decision Sent to Author 第二年3月份，审稿意见回来了，大修。其中一个审稿人疑虑比较多，对我们发现的新现象持有怀疑看法，认为证据不充足，15条大意见条条有针对性；另外的审稿人稍微温和点，总体上肯定了文章的创新性，但是修改意见也不少。主编给了3个月大修时间。 几个主要作者碰头开了几次小组讨论会，制定了补试验方案，两个博士作为主力，几个硕士辅助，一直扎扎实实补试验两个月后发现deadline不够了，又向杂志申请延期1个月。三个月补完试验，一个月修改文章、图片、Response letter。我们的修回信（42页）长度超过了文章（38页）长度了，内容非常丰满，证据可靠，图片漂亮，方法全面，当时自己都觉得文章质量大幅提升，要是不接受可以投15分以上杂志了。在补试验阶段，实验材料和测试成本就花了好多w。 22年七月份投出，结果审稿人很满意，第二轮只用17天，所有审稿人均认为可以直接接受。 -2022年07月02日 Author Approved Converted Files -2022年07月02日 Under Review -2022年07月19日 Decision Made -2022年07月19日 Decision Sent to Author -2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190115, encodeId=6c2421901150d, content=审稿速度:6.0 偏重的研究方向：心脏发育 经验分享：慢！投稿已经5个多月了！还在外审！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4ae5499160, createdName=bwzhang, createdTime=Thu Feb 29 15:31:18 CST 2024, time=2024-02-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2156961, encodeId=68622156961ee, content=偏重的研究方向：肿瘤学 经验分享：投稿已过20天，记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Sun Sep 10 08:26:45 CST 2023, time=2023-09-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165659, encodeId=793621656594a, content=审稿速度:3.0 经验分享：请问各位学长，学姐这个的意思是文章内容不符合期刊要拒稿吗。 Review #2 received Received 29 Oct, 2023 This content is not available. Review #1 received Received 24 Oct, 2023 This content is not available., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7186562135, createdName=ms9000001363974617, createdTime=Mon Oct 30 07:38:54 CST 2023, time=2023-10-30, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2184174, encodeId=7ee321841e410, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单细胞测序 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125b6164757, createdName=ms4000000592594051, createdTime=Fri Jan 26 22:16:32 CST 2024, time=2024-01-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：生物大分子;siRNA;基础医学 经验分享：Stage Start Date Under Review 22nd Aug 23 09:29:31 Author Approved Converted Files 22nd Aug 23 09:29:31 Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问这个是送审，还是还在编辑部，还没到编辑手里？有的人说没有AE assigned，有的说收到邮件了 Stage Start Date Under Review 12th Nov 22 00:30:15 Author Approved Converted Files 12th Nov 22 00:30:15 Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172966, encodeId=257421e296618, content=投稿命中率:25.0 经验分享：写信给编辑部，编辑部回应说编辑决定要2-3个月，这个是认真的吗？ Thank you for your asking. Currently, the paper EMM is under review. I'm sorry I couldn't tell you in detail, and I ask for your understanding. The paper is in the process of the editor checking the paper, and we inform you that it will take about 2-3 months from submission to the first decision letter. Thank you. Sincerely yours, Heehyun Park, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37278348598, createdName=ms7000000868707045, createdTime=Tue Dec 05 09:03:59 CST 2023, time=2023-12-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169916, encodeId=2b31216991665, content=投稿快一个月了，杂志系统一直显示under review。 research square 2023.10.25显示Editor assigned;2023.10.30显示为 submission checks complet...This submission is UNDER CONSIDERATION at Experimental & Molecular Medicine.只能等着吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/B920FCE6F53899E327DE76521BE8DF0F/100, createdBy=f36d2149028, createdName=xiaoyunzju, createdTime=Tue Nov 21 11:05:21 CST 2023, time=2023-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2166339, encodeId=278b216633987, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：审稿速度太慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bff8308329, createdName=ms6000001883965747, createdTime=Thu Nov 02 18:21:11 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省)]

2023-11-21 xiaoyunzju 来自山东省

投稿快一个月了，杂志系统一直显示under review。 research square 2023.10.25显示Editor assigned;2023.10.30显示为 submission checks complet...This submission is UNDER CONSIDERATION at Experimental & Molecular Medicine.只能等着吧

93 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234254, encodeId=7a0d123425458, content=审稿速度:12.0 | 投稿命中率:25.0 经验分享：21年10月投出初稿，第一轮外审太慢了，用了5个月。期间圣诞节、新年，再加上全球疫情，我们没有催稿，只能耐着性子等待： -2021年10月14日 Preliminary Manuscript Data Submitted -2021年10月15日 Author Approved Converted Files -2021年10月15日 Under Review -2022年03月16日 Decision Made -2022年03月16日 Decision Sent to Author 第二年3月份，审稿意见回来了，大修。其中一个审稿人疑虑比较多，对我们发现的新现象持有怀疑看法，认为证据不充足，15条大意见条条有针对性；另外的审稿人稍微温和点，总体上肯定了文章的创新性，但是修改意见也不少。主编给了3个月大修时间。 几个主要作者碰头开了几次小组讨论会，制定了补试验方案，两个博士作为主力，几个硕士辅助，一直扎扎实实补试验两个月后发现deadline不够了，又向杂志申请延期1个月。三个月补完试验，一个月修改文章、图片、Response letter。我们的修回信（42页）长度超过了文章（38页）长度了，内容非常丰满，证据可靠，图片漂亮，方法全面，当时自己都觉得文章质量大幅提升，要是不接受可以投15分以上杂志了。在补试验阶段，实验材料和测试成本就花了好多w。 22年七月份投出，结果审稿人很满意，第二轮只用17天，所有审稿人均认为可以直接接受。 -2022年07月02日 Author Approved Converted Files -2022年07月02日 Under Review -2022年07月19日 Decision Made -2022年07月19日 Decision Sent to Author -2022年07月19日 With NPG, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/21/1b8a115bb4bd3136efd4521b4b663fd0.jpg, createdBy=68f11698384, createdName=Lewisrat, createdTime=Sat Jul 23 14:39:07 CST 2022, time=2022-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190115, encodeId=6c2421901150d, content=审稿速度:6.0 偏重的研究方向：心脏发育 经验分享：慢！投稿已经5个多月了！还在外审！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=e4ae5499160, createdName=bwzhang, createdTime=Thu Feb 29 15:31:18 CST 2024, time=2024-02-29, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2156961, encodeId=68622156961ee, content=偏重的研究方向：肿瘤学 经验分享：投稿已过20天，记录一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=114, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/LXibZVN3MpB1blfiaueaib4iaOtqZg9ZlWgHmqYn3KvVEhfIEicibFxsgJYOj2c9thIBnf6o5mIss0oWYq0z30JnrW4w/132, createdBy=8f7a5200612, createdName=ds666888, createdTime=Sun Sep 10 08:26:45 CST 2023, time=2023-09-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2165659, encodeId=793621656594a, content=审稿速度:3.0 经验分享：请问各位学长，学姐这个的意思是文章内容不符合期刊要拒稿吗。 Review #2 received Received 29 Oct, 2023 This content is not available. Review #1 received Received 24 Oct, 2023 This content is not available., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7186562135, createdName=ms9000001363974617, createdTime=Mon Oct 30 07:38:54 CST 2023, time=2023-10-30, status=1, ipAttribution=黑龙江省), GetPortalCommentsPageByObjectIdResponse(id=2184174, encodeId=7ee321841e410, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：单细胞测序 经验分享：无, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125b6164757, createdName=ms4000000592594051, createdTime=Fri Jan 26 22:16:32 CST 2024, time=2024-01-26, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2155649, encodeId=4f22215564929, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：生物大分子;siRNA;基础医学 经验分享：Stage Start Date Under Review 22nd Aug 23 09:29:31 Author Approved Converted Files 22nd Aug 23 09:29:31 Preliminary Manuscript Data Submitted 22nd Aug 23 04:02:20, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af918292843, createdName=ms6000000371699092, createdTime=Fri Sep 01 20:45:42 CST 2023, time=2023-09-01, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2100901, encodeId=8a632100901b2, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：请问这个是送审，还是还在编辑部，还没到编辑手里？有的人说没有AE assigned，有的说收到邮件了 Stage Start Date Under Review 12th Nov 22 00:30:15 Author Approved Converted Files 12th Nov 22 00:30:15 Preliminary Manuscript Data Submitted 11th Nov 22 22:23:58, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=124, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210112/9d391e0b1cd74e869f11d621441146a1/0f85d4b8f25545bc8cd6ff7d737de80d.jpg, createdBy=8aaa108952, createdName=JayNi, createdTime=Wed Nov 16 16:18:50 CST 2022, time=2022-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172966, encodeId=257421e296618, content=投稿命中率:25.0 经验分享：写信给编辑部，编辑部回应说编辑决定要2-3个月，这个是认真的吗？ Thank you for your asking. Currently, the paper EMM is under review. I'm sorry I couldn't tell you in detail, and I ask for your understanding. The paper is in the process of the editor checking the paper, and we inform you that it will take about 2-3 months from submission to the first decision letter. Thank you. Sincerely yours, Heehyun Park, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=105, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37278348598, createdName=ms7000000868707045, createdTime=Tue Dec 05 09:03:59 CST 2023, time=2023-12-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2169916, encodeId=2b31216991665, content=投稿快一个月了，杂志系统一直显示under review。 research square 2023.10.25显示Editor assigned;2023.10.30显示为 submission checks complet...This submission is UNDER CONSIDERATION at Experimental & Molecular Medicine.只能等着吧, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=93, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://q.qlogo.cn/qqapp/101296147/B920FCE6F53899E327DE76521BE8DF0F/100, createdBy=f36d2149028, createdName=xiaoyunzju, createdTime=Tue Nov 21 11:05:21 CST 2023, time=2023-11-21, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2166339, encodeId=278b216633987, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：审稿速度太慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3bff8308329, createdName=ms6000001883965747, createdTime=Thu Nov 02 18:21:11 CST 2023, time=2023-11-02, status=1, ipAttribution=湖北省)]

2023-11-02 ms6000001883965747 来自湖北省

审稿速度:6.0 | 投稿命中率:50.0
经验分享：审稿速度太慢

87 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务